112 related articles for article (PubMed ID: 15676126)
1. Archaeosomes as adjuvants for combination vaccines.
Patel GB; Zhou H; KuoLee R; Chen W
J Liposome Res; 2004; 14(3-4):191-202. PubMed ID: 15676126
[TBL] [Abstract][Full Text] [Related]
2. Methanobrevibacter smithii archaeosomes-entrapped mzNL4-3 virus-like particles induce specific T helper 1-oriented cellular and humoral responses against HIV-1.
Salmani AS; Aghasadeghi MR; Nategh R; Mokhtari-Azad T; Siadat SD
Curr HIV Res; 2013 Sep; 11(6):491-7. PubMed ID: 24329177
[TBL] [Abstract][Full Text] [Related]
3. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.
Krishnan L; Dicaire CJ; Patel GB; Sprott GD
Infect Immun; 2000 Jan; 68(1):54-63. PubMed ID: 10603368
[TBL] [Abstract][Full Text] [Related]
4. Safety of archaeosome adjuvants evaluated in a mouse model.
Patel GB; Omri A; Deschatelets L; Sprott GD
J Liposome Res; 2002 Nov; 12(4):353-72. PubMed ID: 12519630
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice.
Patel GB; Ponce A; Zhou H; Chen W
J Liposome Res; 2008; 18(2):127-43. PubMed ID: 18569448
[TBL] [Abstract][Full Text] [Related]
6. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
7. A structural comparison of the total polar lipids from the human archaea Methanobrevibacter smithii and Methanosphaera stadtmanae and its relevance to the adjuvant activities of their liposomes.
Sprott GD; Brisson J; Dicaire CJ; Pelletier AK; Deschatelets LA; Krishnan L; Patel GB
Biochim Biophys Acta; 1999 Sep; 1440(2-3):275-88. PubMed ID: 10521711
[TBL] [Abstract][Full Text] [Related]
8. Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2.
Krishnan L; Gurnani K; Dicaire CJ; van Faassen H; Zafer A; Kirschning CJ; Sad S; Sprott GD
J Immunol; 2007 Feb; 178(4):2396-406. PubMed ID: 17277146
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing.
Gurnani K; Kennedy J; Sad S; Sprott GD; Krishnan L
J Immunol; 2004 Jul; 173(1):566-78. PubMed ID: 15210818
[TBL] [Abstract][Full Text] [Related]
10. Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease.
Higa LH; Corral RS; Morilla MJ; Romero EL; Petray PB
Hum Vaccin Immunother; 2013 Feb; 9(2):409-12. PubMed ID: 23291939
[TBL] [Abstract][Full Text] [Related]
11. Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.
McCluskie MJ; Deschatelets L; Krishnan L
Hum Vaccin Immunother; 2017 Dec; 13(12):2772-2779. PubMed ID: 28537465
[TBL] [Abstract][Full Text] [Related]
12. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.
Akache B; Stark FC; Jia Y; Deschatelets L; Dudani R; Harrison BA; Agbayani G; Williams D; Jamshidi MP; Krishnan L; McCluskie MJ
PLoS One; 2018; 13(12):e0208067. PubMed ID: 30513093
[TBL] [Abstract][Full Text] [Related]
13. Archaeosomes with encapsulated antigens for oral vaccine delivery.
Li Z; Zhang L; Sun W; Ding Q; Hou Y; Xu Y
Vaccine; 2011 Jul; 29(32):5260-6. PubMed ID: 21609747
[TBL] [Abstract][Full Text] [Related]
14. Archaeosome immunostimulatory vaccine delivery system.
Patel GB; Chen W
Curr Drug Deliv; 2005 Oct; 2(4):407-21. PubMed ID: 16305444
[TBL] [Abstract][Full Text] [Related]
15. Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice.
Patel GB; Ponce A; Zhou H; Chen W
Int J Toxicol; 2008; 27(4):329-39. PubMed ID: 18821397
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations.
Jia Y; Akache B; Deschatelets L; Qian H; Dudani R; Harrison BA; Stark FC; Chandan V; Jamshidi MP; Krishnan L; McCluskie MJ
Int J Pharm; 2019 Apr; 561():187-196. PubMed ID: 30836154
[TBL] [Abstract][Full Text] [Related]
17. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
18. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ
Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351
[TBL] [Abstract][Full Text] [Related]
19. Angelica sinensis polysaccharide encapsulated into PLGA nanoparticles as a vaccine delivery and adjuvant system for ovalbumin to promote immune responses.
Gu P; Liu Z; Sun Y; Ou N; Hu Y; Liu J; Wu Y; Wang D
Int J Pharm; 2019 Jan; 554():72-80. PubMed ID: 30399435
[TBL] [Abstract][Full Text] [Related]
20. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
